Copyright
©2014 Baishideng Publishing Group Inc.
World J Diabetes. Jun 15, 2014; 5(3): 305-315
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.305
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.305
SGLT inhibitors |
11β-HSD-1 inhibitors |
GKA |
AMPK agonists |
SIRT activators |
PTP-1B inhibitors |
GCGR antagonists |
GR antagonists |
Novel insulin sensitizers |
GPR119 agonists |
Other drugs augmenting GLP-1 secretion: GPR40, G-protein coupled bile acid receptor (TGR5) agonists |
Acyl-CoA: DGAT1 inhibitors |
FGF-21-receptor agonists |
Ranolazine |
Other glucometabolic approaches |
Other metabolic approaches |
Anti-inflammatory approaches |
Induction of immune tolerance |
Pancreatic beta cell protection and regeneration |
Pancreatic islet cell transplantation |
Various antidiabetic approaches |
- Citation: Rochester CD, Akiyode O. Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. World J Diabetes 2014; 5(3): 305-315
- URL: https://www.wjgnet.com/1948-9358/full/v5/i3/305.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i3.305